ArticleInfectious agents and cancer2026
Prevalence of high-risk human papillomavirus genotypes and associated HIV co-infection in Cameroon: a systematic review and meta-analysis.
Article in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-risk human papillomavirus (HR HPV) infection is the primary cause of cervical cancer, a leading cause of cancer mortality among women in sub-Saharan Africa. In Cameroon, there is a gap in synthetized evidence on HR HPV epidemiology, limiting data-driven prevention strategies. This study provides the first comprehensive national synthesis of HR HPV prevalence, genotype distribution, and HIV co-infection among HPV-positive individuals.
methodsA systematic review and meta-analysis were conducted following PRISMA guidelines and registered in PROSPERO (CRD420261282094). We systematically searched PubMed, Scopus, Web of Science, Embase, Cochrane Library, AJOL and local online publishers. Studies reporting the prevalence of HR HPV among sexually active individuals were included. Pooled prevalence estimates were calculated using random-effects models. Heterogeneity was assessed with I2 statistics and explored through subgroup analyses. The methodological quality of included studies was evaluated using the Joanna Briggs Institute (JBI) critical appraisal tools.
resultsA total of 33 studies including 18,798 participants were included in this analysis. The overall pooled prevalence of HR HPV was 28.95% (95% CI: 19.74–40.30; 33 studies; n = 18,798; I2 = 98.7%), with a notable decline from 53.34% before 2014 to 21.43% in 2021–2023. Prevalence varied substantially across populations, being highest among women with precancerous or cancerous lesions (90.69%; 95% CI: 78.48–96.30) and female sex workers (62.10%; 95% CI: 58.08–66.00) compared to women from the general population (21.09%; 95% CI: 15.16–28.55). Among HPV-positive women, HIV co-infection prevalence was 26.17% (95% CI: 13.48–44.65, 19 studies; n = 3,589; I2 = 97.9%), with higher rates in hospital-based studies (34.57%) compared to community-based studies (9.18%). Predominant HR HPV genotypes included HPV16 (28.7%), HPV52 (23.6%), HPV66 (22.9%), HPV33 (22.8%), and HPV18 (20.2%). The pooled prevalence of abnormal cervical lesions among HPV-positive women was 35.15% (95% CI: 20.21–53.70; 12 studies; n = 2,186; I2 = 95.2%), including low-grade lesions (34.4%) and high-grade lesions (19.1%).
conclusionsHR HPV infection remains highly prevalent in Cameroon despite encouraging temporal declines. The substantial burden of HIV co-infection and circulation of multiple oncogenic genotypes underscore the need for integrated HPV–HIV prevention strategies, expanded screening, and consideration of broader-coverage vaccines to accelerate progress toward cervical cancer elimination targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.